C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.
AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) to ...
Study Finds on MSN3d
The Fat Connection: Omega-6 and Triple-Negative Breast CancerIn a nutshell Researchers discovered that omega-6 fatty acids (common in vegetable oils and processed foods) can fuel triple-negative breast cancer growth through a protein called FABP5, while not ...
Experts discuss the patient case of Janet, a 58-year-old with her 2 positive metastatic breast cancer, and after 14 months on ...
HER2-negative breast cancer who have already undergone endocrine therapy and chemotherapy. This antibody-drug conjugate delivers chemotherapy directly to cancer cells, minimizing the impact on ...
During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for ...
Patients and Methods: A total of 320 patients with AOC were centrally screened for HER2 status (243 patients in fi rst line, 77 in relapse). All positive (IHC 3+) and doubtful (IHC 2+) cases were ...
Breaking Down HER2+ Breast Cancer and the Evolution of Treatment HER2-positive — or human epidermal growth factor receptor 2 — breast cancer is one of the disease’s few subtypes and is largely driven ...
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback